The CML stem cell: evolution of the progenitor.
The CML stem cell: evolution of the progenitor.
复制标题
DOI：
10.4161/cc.8.9.8209
复制
发表时间：
2009-05-01
期刊：
影响因子：
--
通讯作者：
Wang JY
中科院分区：
文献类型：
--
作者：
Stuart SA;Minami Y;Wang JY
The success of imatinib mesylate (STI571, Gleevec) in treating chronic myeloid leukemia (CML) is, to date, the crowning achievement of targeted molecular therapy in cancer. Nearly 90% of newly diagnosed patients treated with imatinib in the chronic phase of the disease achieve a complete cytogenetic response. However, more than 95% of these patients retain detectable levels of BCR-ABL mRNA and patients discontinuing imatinib therapy almost invariably relapse, demonstrating that an imatinib insensitive population of leukemia-initiating cells (LICs) persists in nearly all patients. These findings underscore the need for treatments specifically targeting the leukemia-initiating population of CML cells. While mounting evidence suggests that the LIC in the chronic phase of CML is the BCR-ABL positive hematopoietic stem cell, several recent publications suggest that during CML blast crisis, a granulocyte-macrophage progenitor (GMP) population also acquires LIC properties through activation of the β-catenin pathway. Characterization of these cells and evaluation of their sensitivity to imatinib is critical to our understanding and treatment of CML blast crisis.
登录
查看更多内容
影响因子：
82.9
作者：
Castor, A;Nilsson, L;Jacobsen, SEW
通讯作者：
Jacobsen, SEW
影响因子：
2.1
作者：
Abe, Akihiro;Minami, Yosuke;Naoe, Tomoki
通讯作者：
Naoe, Tomoki
影响因子：
158.5
作者：
Druker, Brian J.;Guilhot, Francois;Larson, Richard A.
通讯作者：
Larson, Richard A.
影响因子：
158.5
作者：
Jamieson, CHM;Ailles, LE;Weissman, IL
通讯作者：
Weissman, IL
影响因子：
12.4
作者：
Eramo, A.;Lotti, F.;De Maria, R.
通讯作者：
De Maria, R.